Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna

NEW YORK, September 4, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.

--
Avalonbay Communities Inc. Research Reports
On August 29, 2014, shares of Avalonbay Communities Inc. (Avalonbay) inched 0.95% higher and ended the trading session at $154.10. The stock opened at $153.00 and vacillated between $152.63 and $154.49. The Company's shares are trading near their 52-week high of $156.16, which it made on August 21, 2014. Year-till-date, the stock has gained an upside of 30.34%, outperforming the NYSE Composite, which returned 6.21% during the same time period. The full research reports on Avalonbay are available to download free of charge at:

http://www.analystsreview.com/Sep-04-2014/AVB/report.pdf

--
Digital Realty Trust Inc. Research Reports
On August 19, 2014, Digital Realty Trust, Inc. (Digital Realty) and CenturyLink Technology Solutions, in a joint statement said that they have received The Uptime Institute's Tier III Certification of Facility Construction for their joint venture's data centre located in Tseung Kwan O - the first of its kind in Hong Kong. A. William Stein, Digital Realty, interim CEO and CFO, said, "The Hong Kong facility is one of 20 new Digital Realty data centre projects worldwide for which we have contracted with The Uptime Institute in order to achieve Tier III Design and Facility Certification. This reflects our commitment to provide our clients with resilient and reliable data centre solutions globally." The full research reports on Digital Realty are available to download free of charge at:

http://www.analystsreview.com/Sep-04-2014/DLR/report.pdf

--
Boston Scientific Corporation Research Reports
On August 30, 2014, Boston Scientific Corporation (Boston Scientific) released the primary endpoint results from its Neural Cardiac Therapy for Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stimulation (VNS) for the treatment of heart failure patients. Boston Scientific informed that Faiez Zannad, M.D., Ph.D., Professor of Therapeutics and Cardiology and Director of the Clinical Investigation Center at the Institut National de la Sante et de la Recherche Medicale presented the results at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. As per the Company, the trial did not meet the pre-specified six month primary efficacy endpoint of a reduction in left ventricular end systolic diameter as assessed by a blinded echocardiography core laboratory. Further, Quality of life metrics demonstrated significant symptomatic improvement despite the lack of a significant effect on primary and secondary endpoint measures of cardiac remodeling and functional capacity in heart failure (HF) patients. The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Sep-04-2014/BSX/report.pdf

--
Agilent Technologies Inc. Research Reports
On September 1, 2014, Dako, an Agilent Technologies Inc. (Agilent) company and a worldwide provider of cancer diagnostics, announced the EU launch of HER2 IQFISH pharmDx™ automated on Dako Omnis. According to the Company, the product will assist pathology laboratories to seamlessly integrate the renowned Dako HER2 IQFISH and IQFISH hybridization buffer into their IHC workflow. Commenting on the launch, Jacob Thaysen, Vice President and General Manager for Agilent's Diagnostics and Genomics business, said, "We are committed to improving the speed and accuracy of patient-sample processing and the quality of test performance, because we know these things greatly affect the treatment decisions and outcome for patients." HER2 IQFISH pharmDx™ is known for its nontoxic IQFISH Fast Hybridization Buffer that reduces diagnostic test turnaround time from 18 hours to less than four hours. The Company stated that HER2 IQFISH pharmDx helps in the treatment decision for gastric and breast cancer, as the newly launched product can quantitatively determine HER2 gene amplification in the tumor, allowing oncologists to in turn prescribe potentially life-saving therapies. The full research reports on Agilent are available to download free of charge at:

http://www.analystsreview.com/Sep-04-2014/A/report.pdf

--
Cigna Corp. Research Reports
On August 18, 2014, The Cigna Foundation, supported by Cigna Corp. (Cigna) announced a $100,000 World of Difference grant to Community Solutions to improve the health and sense of security for locals living in Northeast Hartford, Connecticut. According to the Company, the grant will support Community Solutions as the organization works with local partners and residents to improve economic security, education and neighborhood safety. The Company stated that in addition to the grant, Cigna's professional staff is committing countless hours to Community Solutions to help improve life for Northeast Hartford residents. "Through working with our partners in Northeast Hartford, Cigna will leverage our health improvement capabilities to help an underserved population right in our backyard," said Chris Hocevar, a Business Leader at Cigna. "We hope this program will be a model for innovation to coordinate services that can benefit other communities around the nation." The full research reports on Cigna are available to download free of charge at:

http://www.analystsreview.com/Sep-04-2014/CI/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review